中国经济网北京9月4日讯 （记者 康博） 截至8月29日，在有可比业绩的976只（各份额分开计算， 下同）普通股票型基金中，今年前8月业绩实现上涨的基金数量为969只，占比高达99%，仅有7只普通 股基业绩出现下跌。 华安医药生物股票发起式A/C承接此前的上涨态势，以107.64%和107.03%的涨幅位居榜首。也是唯 一一只涨幅翻倍的普通股票型基金。从其二季报看，该基金重仓信达生物、石药集团、康方生物、三生 制药、泽璟制药、百济神州、云顶新耀、信立泰、迈威生物、海南海药。从二级市场走势看，前四只个 股与迈威生物的年内涨幅均翻倍，其中的三生制药更是暴涨超过4倍。 资料显示，华安医药生物股票由桑翔宇管理，其曾任鹏华基金管理有限公司助理研究员，2018年9 月加入华安基金，此前历任投资研究部研究员、基金经理助理。 涨幅在90%以上的普通股基被嘉实、富国与鹏华基金包揽，分别为嘉实互融精选股票A、嘉实互融 精选股票C、富国医药创新股票A、富国医药创新股票C、鹏华医药科技股票A、鹏华医药科技股票C， 涨幅在91.34%至98.55%不等。 而且这三只基金的基金经理全部为资深人士，比如嘉实互融精选的基金经理郝淼，其原为中 ...

Group 1 - In April, among 1016 comparable ordinary stock funds, 171 funds saw an increase in performance, 3 remained flat, and 842 experienced a decline [1][2] - The pharmaceutical and biopharmaceutical sectors emerged as the leading sectors, significantly boosting the performance of related thematic funds [1][2] - Notable funds with over 10% growth in April include Bank of China Health Stock A (12.65%), Bank of China Health Stock C (12.61%), and Penghua Pharmaceutical Technology Stock A (11.65%) [1][2] Group 2 - Bank of China Health Stock A and C's top ten holdings include major companies such as Heng Rui Medicine, Xin Nuo Wei, and Bai Li Tian Heng [1] - Penghua Pharmaceutical Technology Stock A and C, managed by veteran Jin Xiaofei, reported increases of 11.65% and 11.62% respectively, with significant holdings in companies like Nuo Cheng Jian Hua and Bai Ji Shen Zhou [2] - Hua An Pharmaceutical Biotechnology Stock A and C also performed well, with monthly growth rates of 10.91% and 10.88% [2] Group 3 - On the downside, nine ordinary stock funds fell over 10% in April, primarily in the consumer electronics and new energy sectors [3][4] - Minsheng Jia Yin Preferred Stock Fund recorded the largest decline at -13.71%, with major holdings including Haier Smart Home and BYD [3] - Other funds like Dongwu Double Triangle Stock A and C also faced significant declines of 11.09% and 11.14% respectively, largely due to their investments in new energy and internet platforms [4] Group 4 - HSBC Jin Trust Low Carbon Pioneer Stock A and C experienced declines of 10.07% and 10.11%, with all top holdings in new energy stocks [4] - The cumulative return of HSBC Jin Trust Low Carbon Pioneer Stock C since its inception is a loss of 58.24% as of April 30 [4] - The management of these funds includes experienced professionals with extensive backgrounds in research and investment [3][4]

Group 1 - Over 300 active equity funds have reached new year-to-date highs in net value since April 7, driven by structural investment opportunities and a focus on domestic consumption [1][2] - As of April 28, 38 funds achieved new year-to-date highs, with a total of 302 funds since April 7, reflecting a market rebound supported by favorable policies [1][2] - Funds heavily invested in the consumer sector, such as Guotai Consumer Select and Pengyang Consumer Industry Mixed Fund, have shown remarkable performance amid rising domestic demand [1] Group 2 - The Shunwan Lingxin LeRong One-Year Holding Mixed Fund has reported over 30% returns year-to-date, focusing on trendy toys, gold jewelry, and pet-related sectors [2] - The Longcheng Pharmaceutical Industry Selected Mixed Fund has achieved a year-to-date return of 49.78%, with several other pharmaceutical funds also exceeding 35% returns [2] - Fund managers are increasingly adapting their strategies to capture emerging consumption opportunities, moving away from traditional investment paths [3] Group 3 - Fund managers emphasize the importance of understanding consumer demands and adapting to the preferences of younger generations, which is driving a new consumption cycle [3] - Investment strategies are evolving to include a broader range of assets and sectors, focusing on growth stocks, policy-driven companies, and dividend-paying value companies [3]